Skip to main content

Table 2 The positive rate of every methylation marker in cervical precancerous and cancerous lesions

From: Promoter hypermethylation analysis of host genes in cervical intraepithelial neoplasia and cervical cancers on histological cervical specimens

 

The positive rate (n)

P-value

Methylation marker

CIN 1

CIN 2

CIN 3

Cervical Cancer

 

ASTN1

51.6%(48)

72.7%(72)

80.6%(75)

89.2%(99)

0.005*

DLX1

58.1%(54)

78.8%(78)

96.8%(90)

94.6%(105)

0.000*

ITGA4

6.5%(6)

12.1%(12)

32.3%(30)

75.7%(84)

0.000*

RXFP3

29.0%(27)

30.3%(30)

54.8%(51)

83.8% (93)

0.000*

SOX17

38.7%(36)

60.6%(60)

54.8%(51)

86.5%(96)

0.001*

ZNF671

12.9%(12)

30.3%(30)

71.0%(66)

97.3%(108)

0.000*

GynTect®

48.4%(45)

66.7%(66)

80.6%(75)

100.0%(111)

0.000*

  1. CIN Cervical intraepithelial neoplasia, ASTN1 Astrotactin 1, DLX1 Distal-less homeobox 1, ITGA4 Integrin subunit alpha 4, RXFP3 Relaxin family peptide receptor 3, SOX17 SRY-box transcription factor 17, ZNF671 Zinc finger protein 671, GynTect®, a diagnostic test of DNA methylation analysis of a methylation marker panel, the panel comprising six markers (ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671)
  2. *, P < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us